Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 12/20 | 0.64 |
| ▸ | MAOB | P27338 | 8/20 | 0.64 |
| ▸ | AOC2 | O75106 | 6/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | DAO | P14920 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16767243 | 1.00 | AOC3 (0.64) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL16767244 | 1.00 | AOC3 (0.64) | AOC3MAOBAOC2MAOADAO | |
| Hydrochloric Acid SCHEMBL16766591 | 0.99 | AOC3 (0.64) | AOC3MAOBAOC2MAOADAO | |
| Hydrochloric Acid SCHEMBL15527460 | 0.99 | AOC3 (0.64) | AOC3MAOBAOC2MAOADAO | |
| Hydrochloric Acid SCHEMBL15527462 | 0.99 | AOC3 (0.64) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL16767310 | 0.88 | AOC3 (0.59) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL16767311 | 0.88 | AOC3 (0.59) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL16787368 | 0.87 | MAOB (0.58) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL16787366 | 0.86 | AOC3 (0.60) | AOC3MAOBAOC2MAOADAO | |
| SCHEMBL15527585 | 0.86 | AOC3 (0.60) | AOC3MAOBAOC2MAOADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210212968-A1 | COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-07-15 | — | — | US | claimed |
| EP-3528800-A1 | COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2019-08-28 | — | — | EP | claimed |
| US-20190071396-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2019-03-07 | — | — | US | claimed |
| EP-3438087-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2019-02-06 | — | — | EP | claimed |
| US-10160723-B2 | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-25 | — | — | US | claimed |
| WO-2018073154-A1 | COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-04-26 | — | — | WO | claimed |
| US-20180104198-A1 | Pharmaceutical Composition, Methods for Treating and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-04-19 | — | — | US | claimed |
| US-20180086698-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | claimed |
| EP-2844637-B1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2018-03-28 | — | — | EP | claimed |
| US-9302986-B2 | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-05 | — | — | US | claimed |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | PHARMAXIS, LTD. (AU) | 2015-06-11 | — | — | US | claimed |
| US-20210212968-A1 | COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-07-15 | — | — | US | disclosed |
| US-20210212968-A1 | COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-07-15 | — | — | US | disclosed |
| US-20190071396-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2019-03-07 | — | — | US | disclosed |
| US-20190071396-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2019-03-07 | — | — | US | disclosed |
| US-20160244406-A1 | Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-25 | — | — | US | disclosed |
| US-9302986-B2 | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-9302986-B2 | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | PHARMAXIS, LTD. (AU) | 2015-06-11 | — | — | US | disclosed |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | PHARMAXIS, LTD. (AU) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071396-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | AOC3, HAO1, VAPA | AOC3 1/4885MAOB 212/4885AOC2 4/4885 |
| US-20180104198-A1 | Pharmaceutical Composition, Methods for Treating and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | AOC3 268/4885MAOB 1282/4885AOC2 122/4885 |
| US-20160244406-A1 | Substituted 3-Haloallylamine Inhibitors of SSAO and uses thereof | AOC3, HAO1, VAPA | AOC3 1/4885MAOB 212/4885AOC2 4/4885 |
| US-10160723-B2 | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | AOC3, HAO1, VAPA | AOC3 1/4885MAOB 212/4885AOC2 4/4885 |
| US-20180086698-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF SSAO AND USES THEREOF | AOC3, HAO1, VAPA | AOC3 1/4885MAOB 212/4885AOC2 4/4885 |
| US-20210212968-A1 | COMBINATIONS COMPRISING AN SSAO/VAP-1 INHIBITOR AND A SGLT2 INHIBITOR, USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | AOC3 510/4885MAOB 1723/4885AOC2 284/4885 |
| US-20150158813-A1 | SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS OF ASSAO AND USES THEREOF | HAO1, VAPA, AOC3 | AOC3 3/4885MAOB 524/4885AOC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.